Supreme Court ruling on gene patents could mean more opportunities for patients

Dr. Merajver (right) and genetic counselor Kara Milliron meet with a patient.

Dr. Merajver (right) and genetic counselor Kara Milliron meet with a patient.

The U.S. Supreme Court on Thursday ruled unanimously that isolated human genes cannot be patented. The gene patents case involved Myriad Genetics, the company that holds patents on the BRCA1 and BRCA2 genes, which are linked to high risk of breast and ovarian cancer.

We talked to Sofia D. Merajver, M.D., Ph.D., director of the Breast and Ovarian Risk Evaluation Program at the University of Michigan Comprehensive Cancer Center, who has been doing research on hereditary breast and ovarian cancer for 20 years.

mCancer Partner: What does this ruling mean? Continue reading

BRCA Gene Mutations and Cancer

genetic risk breast cancerBRCA gene mutations have been in the news this week since Angelina Jolie announced she has the BRCA1 gene mutation and opted to have a bilateral mastectomy to reduce her risks of developing breast cancer. She became aware of her risk because her mother developed breast cancer in her mid-40s and died at age 56. What exactly are the so-called breast cancer genes and who should be tested to see if they are a carrier?

Continue reading